Arvinas, Inc. (NASDAQ:ARVN) Position Raised by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. increased its position in shares of Arvinas, Inc. (NASDAQ:ARVN) by 71.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,862 shares of the company’s stock after purchasing an additional 25,778 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Arvinas were worth $2,554,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ARVN. McGlone Suttner Wealth Management Inc. acquired a new position in Arvinas in the fourth quarter worth approximately $75,000. Headlands Technologies LLC grew its position in Arvinas by 393.4% in the fourth quarter. Headlands Technologies LLC now owns 2,388 shares of the company’s stock worth $98,000 after buying an additional 1,904 shares during the last quarter. Sectoral Asset Management Inc. grew its position in Arvinas by 13.5% in the third quarter. Sectoral Asset Management Inc. now owns 7,010 shares of the company’s stock worth $138,000 after buying an additional 835 shares during the last quarter. Personal CFO Solutions LLC acquired a new position in Arvinas in the fourth quarter worth approximately $206,000. Finally, Exchange Traded Concepts LLC grew its position in Arvinas by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 5,746 shares of the company’s stock worth $237,000 after buying an additional 1,457 shares during the last quarter. Institutional investors own 95.19% of the company’s stock.

Arvinas Stock Up 3.0 %

Shares of Arvinas stock traded up $0.77 on Friday, hitting $26.62. 4,058,951 shares of the company traded hands, compared to its average volume of 901,188. The company has a 50-day moving average price of $30.35 and a 200 day moving average price of $37.76. Arvinas, Inc. has a 12-month low of $13.57 and a 12-month high of $53.08. The company has a market cap of $1.82 billion, a PE ratio of -4.49 and a beta of 1.98.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.45. Arvinas had a negative net margin of 185.09% and a negative return on equity of 64.79%. The business had revenue of $25.30 million for the quarter, compared to analysts’ expectations of $32.94 million. During the same period in the previous year, the company posted ($1.54) EPS. Arvinas’s revenue was down 22.2% on a year-over-year basis. Equities research analysts anticipate that Arvinas, Inc. will post -4.08 EPS for the current year.

Analysts Set New Price Targets

ARVN has been the topic of several recent research reports. Stifel Nicolaus decreased their price target on shares of Arvinas from $72.00 to $68.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. HC Wainwright reiterated a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research report on Friday, May 17th. Wedbush reiterated an “outperform” rating and set a $57.00 price objective on shares of Arvinas in a research report on Wednesday, May 8th. Wells Fargo & Company lowered their price objective on shares of Arvinas from $63.00 to $60.00 and set an “overweight” rating on the stock in a research report on Thursday, May 9th. Finally, Truist Financial reiterated a “buy” rating and set a $65.00 price objective on shares of Arvinas in a research report on Monday, March 25th. Two equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $61.13.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.